Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis — Subgroup Analyses of the CALIPSO Trial

Kidney International Reports - Tập 5 - Trang 2178-2182 - 2020
Paolo Raggi1, Antonio Bellasi2, Smeeta Sinha3, Jordi Bover4, Mariano Rodriguez5, Markus Ketteler6, David A. Bushinsky7, Rekha Garg8, Joan Perelló9,10, Alex Gold11,12, Glenn M. Chertow12
1Division of Cardiology and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
2Research, Innovation and Brand Reputation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
3Department of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, United Kingdom
4Department of Nephrology, Fundació Puigvert and Universitat Autònoma, IIB Sant Pau, REDinREN, Barcelona, Spain
5Nephrology Unit, Hospital Universitario Reina Sofia, IMIBIC, REDinREN, Córdoba, Spain
6Department of General Internal Medicine and Nephrology, Robert-Bosch-Krankenhaus, Stuttgart, Germany
7Department of Medicine, University of Rochester School of Medicine, Rochester, New York, USA
8PharmaDRS, LLC, San Diego, California, USA
9Research and Development, Sanifit Therapeutics, Palma, Spain
10University of the Balearic Islands, Palma, Spain
11Research and Development, Sanifit Therapeutics, San Diego, California, USA
12Department of Medicine, Stanford University, Palo Alto, California, USA

Tài liệu tham khảo

Nelson, 2020, Targeting vascular calcification in chronic kidney disease, J Am Coll Cardiol Basic Transl Sci, 5, 398 Raggi, 2007, Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis, Nat Clin Pract Cardiovasc Med, 4, 26, 10.1038/ncpcardio0725 Ferrer, 2018, Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification, PLoS ONE, 13, 10.1371/journal.pone.0197061 Raggi, 2020, Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis: results of a randomized phase 2b study, Circulation, 141, 728, 10.1161/CIRCULATIONAHA.119.044195 Bellasi, 2019, Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving hemodialysis with cardiovascular calcification, Clin Kidney J Callister, 1998, Coronary artery disease: improved reproducibility of calcium scoring with an electron-beam CT volumetric method, Radiology, 208, 807, 10.1148/radiology.208.3.9722864 McClelland, 2006, Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA), Circulation, 113, 30, 10.1161/CIRCULATIONAHA.105.580696 Galassi, 2006, Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders, Nephrol Dial Transplant, 21, 3215, 10.1093/ndt/gfl395 Kooman, 2014, Chronic kidney disease and premature ageing, Nat Rev Nephrol, 10, 732, 10.1038/nrneph.2014.185 Chen, 2017, Does statins promote vascular calcification in chronic kidney disease?, Eur J Clin Invest, 47, 137, 10.1111/eci.12718 Raggi, 2011, The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis, Nephrol Dial Transplant, 26, 1327, 10.1093/ndt/gfq725 Urena-Torres, 2013, Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study, Nephrol Dial Transplant, 28, 146, 10.1093/ndt/gfs356 Chertow, 2002, Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients, Kidney Int, 62, 245, 10.1046/j.1523-1755.2002.00434.x Block, 2005, Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis, Kidney Int, 68, 1815, 10.1111/j.1523-1755.2005.00600.x Jamal, 2013, Effect of calcium-based versus non–calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis, Lancet, 382, 1268, 10.1016/S0140-6736(13)60897-1